文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

BCMA-CAR T-cell treatment-associated parkinsonism.

作者信息

Gust Juliane

机构信息

Seattle Children's Research Institute and University of Washington.

出版信息

Blood. 2023 Oct 5;142(14):1181-1183. doi: 10.1182/blood.2023021860.

DOI:10.1182/blood.2023021860
PMID:37796518
Abstract
摘要

相似文献

[1]
BCMA-CAR T-cell treatment-associated parkinsonism.

Blood. 2023-10-5

[2]
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.

Nat Med. 2021-12

[3]
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

J Clin Oncol. 2018-5-29

[4]
Teclistamab impairs detection of BCMA CAR-T cells.

Blood Adv. 2023-8-8

[5]
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.

Hum Gene Ther. 2018-5

[6]
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Mol Ther. 2018-6-18

[7]
High antigen density of BCMA: friend or foe to CAR T cells?

J Immunother Cancer. 2022-9

[8]
Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells.

Blood. 2023-10-5

[9]
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.

Mol Ther. 2019-4-8

[10]
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.

Ann Hematol. 2019-1-28

引用本文的文献

[1]
Neurological complications of CAR T cell therapy for cancers.

Nat Rev Neurol. 2025-6-25

[2]
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.

Blood Adv. 2025-7-22

[3]
Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy.

Cancer Manag Res. 2025-2-19

[4]
Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies.

J Immunother Cancer. 2024-12-22

[5]
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement.

Blood Adv. 2025-3-11

[6]
CAR T-cell therapy to treat multiple myeloma: current state and future directions.

Cancer Metastasis Rev. 2024-12-3

[7]
Immunotherapy-related neurotoxicity in the central nervous system of children with cancer.

Neuro Oncol. 2025-3-7

[8]
New horizons in our understanding of precursor multiple myeloma and early interception.

Nat Rev Cancer. 2024-12

[9]
Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective.

Curr Oncol. 2024-7-6

[10]
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.

Semin Immunopathol. 2024-7-16

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索